Global Major Depressive Disorder Market Growth (Status and Outlook) 2024-2030

Global Major Depressive Disorder Market Growth (Status and Outlook) 2024-2030

Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment. People are affected in different ways by major depression. Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss. Moreover, they can have Others mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.

The global Major Depressive Disorder market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Major Depressive Disorder Industry Forecast” looks at past sales and reviews total world Major Depressive Disorder sales in 2023, providing a comprehensive analysis by region and market sector of projected Major Depressive Disorder sales for 2024 through 2030. With Major Depressive Disorder sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Major Depressive Disorder industry.

This Insight Report provides a comprehensive analysis of the global Major Depressive Disorder landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Major Depressive Disorder portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Major Depressive Disorder market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Major Depressive Disorder and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Major Depressive Disorder.

In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region. The U.S. represents the largest market for major depressive disorder in North America, followed by Canada. In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market. This market in Asia is expected to expand at a significant rate over the next five years. This is due to various companies setting up manufacturing facilities in the region. Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region. India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.

This report presents a comprehensive overview, market shares, and growth opportunities of Major Depressive Disorder market by product type, application, key players and key regions and countries.

Segmentation by type
Drugs Therapy
Biological Therapy
Meditation
Physiothersapy
Others

Segmentation by application
Under 25 Years Old
25-45 Years Old
Above 45 Years Old

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Eli Lilly
H. Lundbeck
Otsuka Pharmaceutical
AstraZeneca
Alkermes
Takeda Pharmaceutical
Naurex
Euthymics Bioscience
E-therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.